RDInvesting Provides Investors with Free In-Depth Equity Reports on AFFY, BMRN, DNDN and HTBX

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://www.rdinvesting.com/ and get exclusive access to our numerous stock reports and market updates.

Affymax, Inc. (OTCMKTS:AFFY - News) shares declined 2.76 percent to close at $1.41 a share Wednesday. The stock traded between $1.40 and $1.48 on volume of 629,045 shares traded. Analysts at WBB Securities have recently downgraded the company’s rating to "hold" from "buy". Shares of Affymax have fallen approximately 93.0 percent year-to-date.

Find out more about Affymax including full access to the free equity report at:
www.RDInvesting.com/AFFY

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - News) shares increased 2.02 percent to close at $77.49 a share Wednesday. The stock traded between $75.08 and $78.83 on volume of 3.19 million shares traded. Analysts at Stifel have recently downgraded the company’s rating to "hold" from "buy". Shares of BioMarin Pharmaceutical have gained approximately 57.0 percent year-to-date.

Find out more about BioMarin Pharmaceutical including full access to the free equity report at:
www.RDInvesting.com/BMRN

Dendreon Corporation (NASDAQ:DNDN - News) shares increased 3.51 percent to close at $3.24 a share Wednesday. The stock traded between $3.18 and $3.34 on volume of 7.34 million shares traded. Analysts at Maxim Group have recently upgraded the company’s rating to "hold" from "sell". Shares of Dendreon have fallen approximately 38.0 percent year-to-date.

Find out more about Dendreon including full access to the free equity report at:
www.RDInvesting.com/DNDN

Heat Biologics Inc. (NASDAQ:HTBX - News) shares increased 9.84 percent to close at $13.39 a share Wednesday. The stock traded between $12.76 and $13.50 on volume of 290,661 shares traded. Analysts at Aegis have recently initiated coverage on the company with a "buy" rating and a price target of $36.00. Shares of Heat Biologics have gained approximately 40.0 percent year-to-date.

Find out more about Heat Biologics including full access to the free equity report at:
www.RDInvesting.com/HTBX

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Research Driven Investing
info@rdinvesting.com